AEON Biopharma, Inc.

Healthcare · Biotechnology · United States

Last price 0.274 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 13.67M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is base...